Skip to main content
OpenTrials
Completed

NCT Number: NCT05486910

Management of Side-Effects of Anti-Acne Treatment by a Cosmetic Routine

Retinoid-based topical acne treatment may induce local tolerance issues such as erythema, dryness, stinging and burning sensations that may reduce adherence and efficacy.

The tested regimen (cream and cleanser) has been specifically developed to rebalance the skin microbiome and compensate side-effects of topical treatments (hydration, skin barrier repair) together with an action on skin imperfections and marks.

This open-label study was conducted in subjects aged 12 years and over with sensitive skin (>2 on a sensitivity composite score from 0-3) treated for at least one month with the fixed-dose gel combination and presenting with treatment-related skin intolerance.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Studio Dermatologia i Kosmetyka

Malbork, Poland

About this study

The study on the evaluation of the management of side-effects of an anti-acne treatment by a cosmetic routine (cleanser and cream) following failure of the usual cosmetic routine has been conducted under dermatological control by Dermscan that is certified by the International Standards Organization (ISO) 9001-2015.

Each study report is subjected to a quality inspection by a proofreader member of Dermscan not involved in the audited study. The inspection of the study report allows to confirm that the results reflect exactly the study raw data and that the study fulfills any standard and regulatory requirements.

Regarding the statistical analysis, data obtained for each parameter, at each measurement time and on each zone are presented in raw value tables. The tables also show the descriptive statistics: means, medians, minima, maxima, standard errors of the means (SEM), confidence intervals of 95% (CI 95%) of these values as well as the variations and percentage variations. They also present the results of the statistical analysis.

Participants have the right to exit from the study at any time and for any motive in compliance with the Helsinki Declaration (1964) and its successive updates. The investigator can also interrupt the subject participation in the study prematurely in the case of a disease occurrence, a pregnancy or the occurrence of an adverse reaction.

The personnel in charge of the study collects data into individual case report forms in electronic or paper format and/or directly from measurement software. When information is collected in paper format, the double data entry is then done from these supports by the designed operator(s), without any interpretation, in specific EXCEL databases. The Project Manager or assistant checks the double data entry by comparing both databases. Then the coherence of the whole data set is checked as well as formulas used in the EXCEL tables (calculation formulas, selected data…). When all the controls are done, the database is locked.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Caucasian;
  • phototype I to IV
  • subject under EPIDUO® with a failed cosmetic routine for more than 1 month.
  • subject agreeing to change their routine (introduction of the EFFACLAR routine).
  • subjects with moderate skin sensitivity: composite score >2 at the inclusion (burning sensation, tightness and itching) with 4 grades: absent, slight, medium and severe
  • subject under anti-acne treatment since 1 month, with an usual routine in failure
  • subject who presents irritated skin due to EPIDUO® treatment

Exclusion criteria

  • pregnant or nursing woman or woman planning a pregnancy during the study
  • cutaneous pathology on the studied zone other than acne (eczema etc.)
  • use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous acceptability of the study product (according to the investigator's appreciation, except the anti-acne treatment Epiduo and former cosmetic routine)
  • oral treatment of retinoids during the six previous months of the study
  • any change in hormonal treatment (including contraceptive) during the three previous months of the study or subject under Androcur® generic) treatments since less than six months
  • professional facial care during the study or within the previous month
  • subject manipulating her/ his acne lesions
  • excessive exposure to sunlight or UV-rays within the previous month

Treatment and study plan

Primary outcomes

  1. change in comedogenic potential

    Time frame: from baseline to Day28

    counting of retentional and inflammatory elements on the whole face. Descriptive statistics are done in order to determine the variation significance.

  2. change in Global Evaluation Acne (GEA) score

    Time frame: from baseline to Day28

    The dermatologist realizes clinical score on the face using the Investigator Global Acne Severity Score : from 0 Clear. No lesions to 5 Very severe.

Secondary outcomes

  1. change in sensitivity score by the dermatologist

    Time frame: from baseline to Day28

    evaluation of the parameters erythema, dryness, desquamation on a 0-3 scale

  2. change in sensitivity score by the participant (composite score)

    Time frame: from baseline to Day28

    evaluation of the parameters itching, tightness, burning sensation on a 0-3 scale

  3. change in global tolerance score by the dermatologist

    Time frame: from baseline to Day28

    evaluation of the tolerance on a 0-3 scale

  4. change in global tolerance score by the participant

    Time frame: from baseline to Day28

    evaluation of the tolerance on a 0-3 scale

  5. change in overall effectiveness score by the dermatologist

    Time frame: from baseline to Day28

    evaluation of the effectiveness on a 0-3 scale

  6. change in overall effectiveness score by the participant

    Time frame: from baseline to Day28

    evaluation of the effectiveness on a 0-3 scale

  7. change in quality of life

    Time frame: from baseline to Day28

    Cardiff Acne Disability Index (CADI) questionnaire with 5 questions

Sponsors and collaborators

Lead sponsor

Cosmetique Active International

Industry

Registry information

Official study title

Evaluation of the Management of Side-Effects of Anti-Acne Treatment by a Cosmetic Routine Following Failure of the Usual Cosmetic Routine

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Aug 4, 2022
Registry last updated
Aug 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.